萨丽-嘎日迪+协日嘎-4味汤与肾复康对糖尿病肾病患者降尿蛋白的对比性研究

Comparison of Urine-reducing Protein in Patients with Diabetic Nephropathy Treated with Sali-Garidi+Xieriga-4weitang and Shenfukang

为了探讨萨丽-嘎日迪+协日嘎-4味汤与肾复康对糖尿病肾病患者的治疗效果,本研究选择我院确诊的糖尿病肾病患者100例作为研究对象,按照随机字母表法分为两组,每组50例。观察组患者采用萨丽-嘎日迪+协日嘎-4味汤治疗,对照组患者采用肾复康治疗。比较两组患者的治疗效果、24h尿蛋白水平、尿白蛋白排泄率,并检测两组患者的肝功能、肾功能和血常规变化。研究结果表明,观察组的有效率(88.00%)显著高于对照组(74.00%)(p=0.037)。治疗2周后两组患者的24h尿蛋白和尿白蛋白排泄率均显著下降(p<0.05),然而,观察组的24h尿蛋白和尿白蛋白排泄率均显著低于对照组(p<0.05)。治疗前后观察组和对照组糖尿病肾病患者的肝功能、肾功能和血常规均无显著差异(p>0.05)。研究的初步结论表明,萨丽-嘎日迪+协日嘎-4味汤在治疗糖尿病肾病方面疗效显著高于肾复康,可显著降低患者尿蛋白水平,并且安全性高。

To investigate the therapeutic effects of Sali-Garidi+Xieriga-4weitang and Shenfukang on patients with diabetic nephropathy. During the period from January 2016 to June 2017, 100 patients with diabetic nephropathy diagnosed in our hospital were selected as the study subjects. They were divided into two groups according to the randomized alphabetic method, with 50 cases in each group. The patients in the observation group were treated with Sali-Garidi+Xieriga-4weitang, while the patients in the control group were treated with Shenfukang. The treatment effect, 24-hour urinary protein level, and urinary albumin excretion rate were compared between the two groups, and the liver function, renal function, and blood routine changes were detected in both groups. The results showed that the rate of efficacy in the observation group (88.00%) was significantly higher than that in the control group (74.00%)(p=0.037). After 2 weeks of treatment, the 24-hour urinary protein and urinary albumin excretion rate of both groups were significantly decreased (p<0.05). However, the 24-hour urinary protein and urinary albumin excretion rates were significantly lower in the observation group than in the control group (p<0.05). There was no significant difference in liver function, renal function and blood routine between the observation group and the control group (p>0.05). Preliminary findings suggest that the efficacy of Sali-Garidi+Xieriga-4weitang in the treatment of diabetic nephropathy is significantly higher than that of Shenfukang, which can significantly reduce the level of urinary protein in patients, and with high safety.